Skip to main content
Top
Published in: Clinical and Experimental Medicine 2/2023

Open Access 21-03-2022 | Vulgar Psoriasis | Review Article

Paraoxonase and arylesterase activity of serum PON-1 enzyme in psoriatic patients: a systematic review and meta-analysis

Authors: Stefania Bassu, Arduino A. Mangoni, Rosanna Satta, Dario Argiolas, Ciriaco Carru, Angelo Zinellu

Published in: Clinical and Experimental Medicine | Issue 2/2023

Login to get access

Abstract

Human serum paraoxonase-1 (PON-1) is a critical antioxidant defense system against lipid oxidation. Decreased PON-1 activity has been associated with systemic oxidative stress in several disease states. We conducted a systematic review and meta-analysis of plasma/serum concentrations of PON-1 paraoxonase and arylesterase activity in psoriasis, a chronic immune-mediated and inflammatory skin disease. The electronic databases PubMed, Web of Science, and Scopus were searched from inception to November 2021. In total, 14 studies in 691 psoriatic patients and 724 healthy controls were included in the meta-analysis. Serum paraoxonase activity was significantly lower in psoriatic patients (SMD = − 2.30, 95% CI − 3.17 to − 1.42; p < 0.001); however, no significant between-group differences were observed in serum arylesterase activity (SMD = − 0.34, 95% CI − 0.11 to 0.80; p = 0.14). The pooled SMD values were not substantially altered in sensitivity analysis. There was no publication bias. In conclusion, our meta-analysis has shown that serum paraoxonase, but not arylesterase, activity is significantly lower in psoriasis, suggesting an impaired antioxidant defense in these patients.
Literature
1.
go back to reference Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 1999;140:1–7.PubMedCrossRef Ortonne JP. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol. 1999;140:1–7.PubMedCrossRef
2.
go back to reference Simonetti O, Ferretti G, Salvi A, Offidani AM, Bossi G. Plasma lipid changes in psoriatic children. Dermatology. 1992;185:96–100.PubMedCrossRef Simonetti O, Ferretti G, Salvi A, Offidani AM, Bossi G. Plasma lipid changes in psoriatic children. Dermatology. 1992;185:96–100.PubMedCrossRef
3.
go back to reference Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediat Inflamm. 2010;2010:535612.CrossRef Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediat Inflamm. 2010;2010:535612.CrossRef
4.
go back to reference Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediat Inflamm. 2007;2007:78454. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediat Inflamm. 2007;2007:78454.
5.
go back to reference Coimbra S, Oliveira H, Reis F, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55:202–4.PubMedCrossRef Coimbra S, Oliveira H, Reis F, et al. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatol Sci. 2009;55:202–4.PubMedCrossRef
6.
go back to reference Kaur S, Zilmer K, Leping V, Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25:1328–33.PubMedCrossRef Kaur S, Zilmer K, Leping V, Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25:1328–33.PubMedCrossRef
7.
go back to reference Kural BV, Orema A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant–antioxidant system in patients with psoriasis. Clin Chim Acta. 2003;328:71–82.CrossRef Kural BV, Orema A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant–antioxidant system in patients with psoriasis. Clin Chim Acta. 2003;328:71–82.CrossRef
8.
go back to reference Kokcam I, Naziroglu M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta. 1999;289:23–31.PubMedCrossRef Kokcam I, Naziroglu M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta. 1999;289:23–31.PubMedCrossRef
9.
go back to reference Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta. 2009;410:1–12.PubMedCrossRef Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta. 2009;410:1–12.PubMedCrossRef
10.
go back to reference Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129–35.PubMedCrossRef Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129–35.PubMedCrossRef
11.
go back to reference Aldridge WN. Serum esterases II. An enzyme hydrolysing diethyl pnitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J. 1953;53:117–24.PubMedPubMedCentralCrossRef Aldridge WN. Serum esterases II. An enzyme hydrolysing diethyl pnitrophenyl phosphate (E600) and its identity with the A-esterase of mammalian sera. Biochem J. 1953;53:117–24.PubMedPubMedCentralCrossRef
12.
go back to reference Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Investig. 1995;96:2882–91.PubMedPubMedCentralCrossRef Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Investig. 1995;96:2882–91.PubMedPubMedCentralCrossRef
13.
go back to reference Canales A, Sanchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin (Barc). 2003;121:537–48.PubMedCrossRef Canales A, Sanchez-Muniz FJ. Paraoxonase, something more than an enzyme? Med Clin (Barc). 2003;121:537–48.PubMedCrossRef
14.
go back to reference Shih DM, Lusis AJ. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol. 2009;20(4):288–92.PubMedCrossRef Shih DM, Lusis AJ. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol. 2009;20(4):288–92.PubMedCrossRef
15.
go back to reference Tang WH, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32(11):2803–12.PubMedPubMedCentralCrossRef Tang WH, Hartiala J, Fan Y, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32(11):2803–12.PubMedPubMedCentralCrossRef
16.
go back to reference Moola S, Munn Z, Tufanaru C, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors., et al., Joanna Briggs Institute reviewer’s manual. Adelaide: Johanna Briggs Institute; 2017. Moola S, Munn Z, Tufanaru C, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors., et al., Joanna Briggs Institute reviewer’s manual. Adelaide: Johanna Briggs Institute; 2017.
17.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum; 1988. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum; 1988.
18.
19.
go back to reference Zhang Y, Coello PA, Guyatt GH, et al. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83–93.PubMedCrossRef Zhang Y, Coello PA, Guyatt GH, et al. GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences-inconsistency, imprecision, and other domains. J Clin Epidemiol. 2019;111:83–93.PubMedCrossRef
20.
22.
23.
go back to reference Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.PubMedPubMedCentralCrossRef Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med Res Methodol. 2011;11:41.PubMedPubMedCentralCrossRef
24.
go back to reference Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
25.
go back to reference Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8(47):15–7. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull. 1999;8(47):15–7.
26.
go back to reference Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRef
27.
go back to reference Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046–55.PubMedCrossRef Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046–55.PubMedCrossRef
28.
go back to reference Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.PubMedCrossRef
29.
go back to reference Toker A, Kadi M, Yildirim AK, Aksoy H, Akçay F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct. 2009;27(3):176–80.PubMedCrossRef Toker A, Kadi M, Yildirim AK, Aksoy H, Akçay F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct. 2009;27(3):176–80.PubMedCrossRef
30.
go back to reference Ferretti G, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol. 2012;166(1):204–7.PubMedCrossRef Ferretti G, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol. 2012;166(1):204–7.PubMedCrossRef
31.
go back to reference Usta M, Turan E, Aral H, Inal BB, Gurel MS, Guvenen G. Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome. J Clin Lab Anal. 2011;25(4):289–95.PubMedPubMedCentralCrossRef Usta M, Turan E, Aral H, Inal BB, Gurel MS, Guvenen G. Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome. J Clin Lab Anal. 2011;25(4):289–95.PubMedPubMedCentralCrossRef
32.
go back to reference Asefi M, Vaisi-Raygani A, Bahrehmand F, et al. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol. 2012;167(6):1279–86.PubMedCrossRef Asefi M, Vaisi-Raygani A, Bahrehmand F, et al. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol. 2012;167(6):1279–86.PubMedCrossRef
33.
go back to reference Emre S, Metin A, Demirseren DD, Kilic S, Isikoglu S, Erel O. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol. 2013;27(3):e370–5.PubMedCrossRef Emre S, Metin A, Demirseren DD, Kilic S, Isikoglu S, Erel O. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. J Eur Acad Dermatol Venereol. 2013;27(3):e370–5.PubMedCrossRef
34.
go back to reference Ramadan R, Tawdy A, Abdel Hay R, Rashed L, Tawfik D. The antioxidant role of paraoxonase 1 and vitamin E in three autoimmune diseases. Skin Pharmacol Physiol. 2013;26(1):2–7.PubMedCrossRef Ramadan R, Tawdy A, Abdel Hay R, Rashed L, Tawfik D. The antioxidant role of paraoxonase 1 and vitamin E in three autoimmune diseases. Skin Pharmacol Physiol. 2013;26(1):2–7.PubMedCrossRef
35.
go back to reference He L, Qin S, Dang L, et al. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. Biochim Biophys Acta. 2014;1841(12):1709–15.PubMedCrossRef He L, Qin S, Dang L, et al. Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. Biochim Biophys Acta. 2014;1841(12):1709–15.PubMedCrossRef
36.
go back to reference Holzer M, Wolf P, Inzinger M, et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Investig Dermatol. 2014;134(3):635–42.PubMedCrossRef Holzer M, Wolf P, Inzinger M, et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Investig Dermatol. 2014;134(3):635–42.PubMedCrossRef
37.
go back to reference Nemati H, Khodarahmi R, Sadeghi M, Ebrahimi A, Rezaei M, Vaisi-Raygani A. Antioxidant status in patients with psoriasis. Cell Biochem Funct. 2014;32(3):268–73.PubMedCrossRef Nemati H, Khodarahmi R, Sadeghi M, Ebrahimi A, Rezaei M, Vaisi-Raygani A. Antioxidant status in patients with psoriasis. Cell Biochem Funct. 2014;32(3):268–73.PubMedCrossRef
38.
go back to reference Husni ME, Wilson Tang WH, Lucke M, Chandrasekharan UM, Brennan DM, Hazen SL. Correlation of high-density lipoprotein-associated paraoxonase 1 activity with systemic inflammation, disease activity, and cardiovascular risk factors in psoriatic disease. Arthritis Rheumatol. 2018;70(8):1240–50.PubMedCrossRef Husni ME, Wilson Tang WH, Lucke M, Chandrasekharan UM, Brennan DM, Hazen SL. Correlation of high-density lipoprotein-associated paraoxonase 1 activity with systemic inflammation, disease activity, and cardiovascular risk factors in psoriatic disease. Arthritis Rheumatol. 2018;70(8):1240–50.PubMedCrossRef
39.
go back to reference Sorokin AV, Kotani K, Elnabawi YA, et al. Association between oxidation-modified lipoproteins and coronary plaque in psoriasis. Circ Res. 2018;123(11):1244–54.PubMedPubMedCentralCrossRef Sorokin AV, Kotani K, Elnabawi YA, et al. Association between oxidation-modified lipoproteins and coronary plaque in psoriasis. Circ Res. 2018;123(11):1244–54.PubMedPubMedCentralCrossRef
40.
go back to reference Bacchetti T, Simonetti O, Ricotti F, Offidani A, Ferretti G. Plasma oxidation status and antioxidant capacity in psoriatic children. Arch Dermatol Res. 2020;312(1):33–9.PubMedCrossRef Bacchetti T, Simonetti O, Ricotti F, Offidani A, Ferretti G. Plasma oxidation status and antioxidant capacity in psoriatic children. Arch Dermatol Res. 2020;312(1):33–9.PubMedCrossRef
41.
go back to reference Oszukowska M, Kozłowska M, Kaszuba A. Paraoxonase-1 and other factors related to oxidative stress in psoriasis. Postepy Dermatol Alergol. 2020;37(1):92–6.PubMedPubMedCentralCrossRef Oszukowska M, Kozłowska M, Kaszuba A. Paraoxonase-1 and other factors related to oxidative stress in psoriasis. Postepy Dermatol Alergol. 2020;37(1):92–6.PubMedPubMedCentralCrossRef
42.
go back to reference Shakoei S, Nakhjavani M, Mirmiranpoor H, Motlagh MA, Azizpour A, Abedini R. The serum level of oxidative stress and antioxidant markers in patients with psoriasis: a cross-sectional study. Clin Aesthet Dermatol. 2021;14(7):38–41. Shakoei S, Nakhjavani M, Mirmiranpoor H, Motlagh MA, Azizpour A, Abedini R. The serum level of oxidative stress and antioxidant markers in patients with psoriasis: a cross-sectional study. Clin Aesthet Dermatol. 2021;14(7):38–41.
43.
go back to reference Rosta V, Trentini A, Passaro A, et al. Sex difference impacts on the relationship between Paraoxonase-1 (PON1) and type 2 diabetes. Antioxidants (Basel). 2020;9(8):683.PubMedCrossRef Rosta V, Trentini A, Passaro A, et al. Sex difference impacts on the relationship between Paraoxonase-1 (PON1) and type 2 diabetes. Antioxidants (Basel). 2020;9(8):683.PubMedCrossRef
44.
go back to reference Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567:12–21.PubMedPubMedCentralCrossRef Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567:12–21.PubMedPubMedCentralCrossRef
45.
go back to reference Bacchetti T, Campanati A, Ferreti G, Simonetti O, Liberati G, Offidani AM. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-alpha inhibitor treatment. Br J Dermatol. 2013;168:984–9.PubMedCrossRef Bacchetti T, Campanati A, Ferreti G, Simonetti O, Liberati G, Offidani AM. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-alpha inhibitor treatment. Br J Dermatol. 2013;168:984–9.PubMedCrossRef
46.
go back to reference Pektas SD, Akoglu G, Metin A, Neselioglu S, Erel O. Evaluation of systemic oxidant/antioxidant status and paraoxonase 1 enzyme activities in psoriatic patients treated by narrow band ultraviolet B phototherapy. Red Rep. 2013;18:200–4.CrossRef Pektas SD, Akoglu G, Metin A, Neselioglu S, Erel O. Evaluation of systemic oxidant/antioxidant status and paraoxonase 1 enzyme activities in psoriatic patients treated by narrow band ultraviolet B phototherapy. Red Rep. 2013;18:200–4.CrossRef
47.
go back to reference Kilic S, Emre S, Metin A, Isikoglu S, Erel O. Effect of the systemic use of methotrexate on the oxidative stress and paraoksonase enzyme in psoriasis patients. Arch Dermatol Res. 2013;305:495–500.PubMedCrossRef Kilic S, Emre S, Metin A, Isikoglu S, Erel O. Effect of the systemic use of methotrexate on the oxidative stress and paraoksonase enzyme in psoriasis patients. Arch Dermatol Res. 2013;305:495–500.PubMedCrossRef
48.
go back to reference Asefi M, Vaisi-Raygani A, Bahrehmand F, et al. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol. 2012;167:1279–86.PubMedCrossRef Asefi M, Vaisi-Raygani A, Bahrehmand F, et al. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis. Br J Dermatol. 2012;167:1279–86.PubMedCrossRef
49.
go back to reference Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA J Am Med Assoc. 2008;299:1265–76.CrossRef Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA J Am Med Assoc. 2008;299:1265–76.CrossRef
50.
go back to reference Rodríguez-Carrio J, López-Mejías R, Alperi-López M, López P, Ballina-García FJ, González-Gay MÁ, et al. Paraoxonase 1 activity is modulated by the rs662 polymorphism and IgG anti-high-density lipoprotein antibodies in patients with rheumatoid arthritis: potential implications for cardiovascular disease. Arthritis Rheumatol. 2016;68:1367–76.PubMedCrossRef Rodríguez-Carrio J, López-Mejías R, Alperi-López M, López P, Ballina-García FJ, González-Gay MÁ, et al. Paraoxonase 1 activity is modulated by the rs662 polymorphism and IgG anti-high-density lipoprotein antibodies in patients with rheumatoid arthritis: potential implications for cardiovascular disease. Arthritis Rheumatol. 2016;68:1367–76.PubMedCrossRef
51.
go back to reference Arslan A, Tüzün FA, Arslan H, Demir H, Tamer S, Demir C, et al. The relationship between serum paraoxonase levels and carotid atherosclerotic plaque formation in Alzheimer’s patients. Neurol Neurochir Pol. 2016;50:403–9.PubMedCrossRef Arslan A, Tüzün FA, Arslan H, Demir H, Tamer S, Demir C, et al. The relationship between serum paraoxonase levels and carotid atherosclerotic plaque formation in Alzheimer’s patients. Neurol Neurochir Pol. 2016;50:403–9.PubMedCrossRef
52.
go back to reference Meisinger C, Freuer D, Bub A, Linseisen J. Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: a cross-sectional study. Lipids Health Dis. 2021;20:81.PubMedPubMedCentralCrossRef Meisinger C, Freuer D, Bub A, Linseisen J. Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: a cross-sectional study. Lipids Health Dis. 2021;20:81.PubMedPubMedCentralCrossRef
53.
go back to reference Scrivo R, Vasile M, Bartosiewicz I, Valesini G. Inflammation as “common soil” of the multifactorial diseases. Autoimmun Rev. 2011;10:369–74.PubMedCrossRef Scrivo R, Vasile M, Bartosiewicz I, Valesini G. Inflammation as “common soil” of the multifactorial diseases. Autoimmun Rev. 2011;10:369–74.PubMedCrossRef
Metadata
Title
Paraoxonase and arylesterase activity of serum PON-1 enzyme in psoriatic patients: a systematic review and meta-analysis
Authors
Stefania Bassu
Arduino A. Mangoni
Rosanna Satta
Dario Argiolas
Ciriaco Carru
Angelo Zinellu
Publication date
21-03-2022
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2023
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-022-00818-z

Other articles of this Issue 2/2023

Clinical and Experimental Medicine 2/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare